A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients.

Rajpal, Rajesh; Dowling, Paul; Meiller, Justine; Clarke, Colin; Murphy, William G; O'Connor, Robert; Kell, Malcolm; Mitsiades, Constantine; Richardson, Paul; Anderson, Kenneth C; Clynes, Martin; O'Gorman, Peter

Rajpal, Rajesh; Dowling, Paul; Meiller, Justine; Clarke, Colin; Murphy, William G; O'Connor, Robert; Kell, Malcolm; Mitsiades, Constantine; Richardson, Paul; Anderson, Kenneth C; Clynes, Martin; O'Gorman, Peter.

Affiliation

Rajpal R; National Institute for Cellular Biotechnology (NICB), Dublin City University, Dublin, Ireland.

Proteomics ; 11(8): 1391-402, 2011 Apr.

Article in En | MEDLINE | ID: mdl-21365752

Subject(s)

Biomarkers, Tumor/blood; Multiple Myeloma/drug therapy; Thalidomide/therapeutic use; Aged; Aged, 80 and over; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Profiling; Humans; Male; Mass Spectrometry; Middle Aged; Multiple Myeloma/blood; Prognosis; Sensitivity and Specificity; Thalidomide/administration & dosage; Thalidomide/adverse effects; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thalidomide / Biomarkers, Tumor / Multiple Myeloma Type of study: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Proteomics Journal subject: BIOQUIMICA Year: 2011 Type: Article Affiliation country: Ireland

Fulltext

XML

PubMed Links

Search on Google